title: [Therapeutic trials in arterial hypertension].
abstract: Therapeutic trials in hypertension taught us that a strategy based on a thiazide diuretic, or a beta-blocker as first-line drug, has reduced significantly the incidence of stroke (relative risk reduction: -35%), major coronary events (-14%), cardiovascular death (-18%) and heart failure (-42%). The level of cardiovascular risk, taking into account classical risk factors, multiplied by relative risk, offers the best estimate of therapeutic absolute benefit. In terms of prevention, being treated seems to be more important than the level of blood pressure that has been reached.
authors.affiliation: Service de cardiologie, Hôpital Louis-Pradel, Lyon.
authors.forename: F
authors.initials: F
authors.lastname: Gueyffier
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001581:Benzothiadiazines; D001794:Blood Pressure / Q000187:drug effects; D002303:Cardiac Output, Low / Q000517:prevention & control; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control; D004232:Diuretics; D006331:Heart Diseases / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D015994:Incidence; D012307:Risk Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors